<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Breast Cancer Research</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5A8676AF-C11B-4A4D-B5F2-0080C40C4E02"><gtr:id>5A8676AF-C11B-4A4D-B5F2-0080C40C4E02</gtr:id><gtr:firstName>Pascal</gtr:firstName><gtr:surname>Meier</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FM019217%2F1"><gtr:id>CABAE4D1-D5CA-4C9F-9164-02A220731E6B</gtr:id><gtr:title>Harnessing TNF-mediated cell death in cancer</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M019217/1</gtr:grantReference><gtr:abstractText>Inflammation and cell death are ancient processes of fundamental biological importance that enable survival and adaptation during infection and injury. Tumour necrosis factor (TNF) is the prototypical proinflammatory cytokine that signals, through its type 1 receptor (TNF-R1), either cell survival, cell proliferation or cell death1. TNF stimulates an inflammatory response whose 'purpose' is to remove the source of the disturbance, allowing the host to adapt to an abnormal condition, and, ultimately, to restore functionality and homeostasis to the tissue. However, when deregulated, inflammation can drive chronic remodelling and tissue repair, which contributes to chronic inflammatory diseases, cancer and treatment failure. 

The principle idea addressed by this application is that cell survival and adaptation mechanisms of tumours are supported, at least in part, by cancer-related inflammation, and that this can be successfully targeted by switching the TNF response from pro-inflammation to cell death. Despite clear evidence that TNF can signal cell survival and death, the mechanisms that can switch between the distinct biological outcomes remain elusive. This is important as its resolution, and putative therapeutic intervention, would allow the diversion of cancer-related inflammation into activation of cell death. Our starting point for this proposal is substantial new data on the regulation of TNF-signalling and cell death. 

We identified that the Ub-receptor function of cIAP1 critically controls TNF signalling, selectively regulating the pro-death effects of TNF, without inhibiting the NFkB pathway. Our preliminary data indicate that a point mutation in the Ub-binding domain of cIAP1 switches the TNF response to cell death, and completely blocks tumorigenesis. Here, we propose to use mouse models, imaging, and biochemical approaches to decipher how the Ub-receptor function of cIAP1 regulates TNF-induced cell death, and whether switching the TNF response from pro-inflammation to cell death causes tumours to permanently regress. 

Cytokines of the TNF-superfamily are classic inducers of programmed necrosis (necroptosis). Although anticancer therapies that trigger the necrotic death of tumour cells may be particularly attractive to overcome apoptosis resistance, because TNF-induced necroptosis also facilitates inflammation, and deregulated inflammation can also support tumorigenesis, it will be important to carefully examine the physiological and pathological consequence of stimulating TNF-induced necrosis. At present, there is no clear evidence to indicate whether necrosis is beneficial or harmful in cancers. Here we will determine the therapeutic opportunities and pathological consequences of manipulating TNF signalling in cancer.

Given that TNF plays an eminent role in diverse pathological processes at the core of human diseases, our findings will provide new avenues for therapeutic intervention strategies.</gtr:abstractText><gtr:technicalSummary>Deregulated cell death and inflammation can drive chronic remodelling and tissue repair, which can contribute to cancer and treatment failure. The principle idea addressed by this application is that cell survival and adaptation mechanisms of tumours are supported, at least in part, by cancer-related inflammation, and that this can be successfully targeted by switching the TNF response from pro-inflammation to activation of cell death, causing tumours to permanently regress. 

Despite clear evidence that TNF can signal cell survival and death, the mechanisms that can switch between the distinct biological outcomes remain elusive. This is important as its resolution, and putative therapeutic intervention, would allow the diversion of cancer-related inflammation into activation of cell death. Our starting point for this proposal is substantial new data on the regulation of TNF-signalling and cell death. 

We identified that the Ub-receptor function of cIAP1 critically controls TNF signalling, selectively regulating the pro-death effects of TNF, without inhibiting the NFkB pathway. Our preliminary data indicate that a point mutation in the Ub-binding domain of cIAP1, which abrogates its ability to bind to M1- and K63-linked Ub chains, switches the TNF response to cell death, and completely blocks tumorigenesis. Mechanistically, we find that the Ub-binding domain of cIAP1 regulates intracellular trafficking of TNF-R1, and the consequences of RIPK1 ubiquitylation. Our data are consistent with a scenario whereby Ub-binding of cIAP1 participates with ESCRT-0 in capturing and sorting ubiquitylated TNF-R1 and RIPK1 for recycling.

Here, we propose to use mouse models, imaging, and biochemical approaches to decipher how the Ub-receptor function of cIAP1 regulates TNF-induced cell death, and whether switching the TNF response from pro-inflammation to cell death is beneficial or harmful in cancer.</gtr:technicalSummary><gtr:potentialImpactText>Impact and potential beneficiaries of this research: 

-Scientific community:
The successful conclusion of the proposed project is expected to provide a better understanding of the molecular mechanisms that control Ubiquitin (Ub)-dependent regulation of signal transduction pathways that influence the ability of multi-cellular organisms to adapt to perturbations. As such our research addresses fundamental issues relevant to normal animal physiology and following exposure to stress. Further, as Ub-mediated regulation of cell death and tissue repair is involved in almost every aspect of life, the proposed project will also impact the health-care community. Of particular interest is the notion that cell death regulatory proteins also fulfill nonlethal functions in differentiation and tissue remodeling. It is now clear that the cell death machinery is involved in releasing signals to communicate with their cellular environment, to promote cell division, tissue regeneration, and wound healing. Unraveling the molecular details governing this process could lead to a better understanding of aging, tissue regeneration and cancer.

- Cancer patients: 
One of the key problems in cancer is the adaptive nature of tumours. It is now recognised that the Ub system modulates key signal transduction pathways that have direct implications in the 'evolvability' of tumours. Hence, cancer treatments would be significantly more successful if it was possible to target Ub-dependent signalling events. Our research addresses a fundamental aspect of Ub-dependent tissue repair. Ultimately, this work will provide new insights into the mechanisms through which Ub-dependent signalling contributes to cancer, and how we can translate this information for patient benefit.

- Public sector, Academia/Pharma based drug development teams:
Given TNF's importance under physiological and pathological conditions, and its central role in chronic inflammatory diseases, inflammation-associated cancer, and cancer-related inflammation, the results of this project will be of significant interest not only for academic but also private drug development groups. The identification of the molecular mechanisms through which TNF signalling can be switched from pro-inflammation to cell death will open up new avenues for therapeutic intervention strategies. It is anticipated that a clinical trial could follow from this study within five years. This will have obvious benefits in health and well being affecting the public sector, and can be exploited by the industry for the development of novel technologies for prevention and therapy of liver cancer in the early phases of the disease.

- General public, schools: 
The project is a clear-cut example of the development of suitable experimental models for understanding the mechanism of disease and to develop new methods for prevention and cure. Thus results arising from the project can be used to illustrate the process in education, leading to obvious cultural benefits by emphasizing the importance of scientific approaches in health care.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>373002</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lausanne</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>The role of IAPs and cytokine signalling in pancreatic cancer</gtr:description><gtr:id>B8E94B9E-9BD5-42FF-A11A-3F1F395C4B2D</gtr:id><gtr:impact>not yet available</gtr:impact><gtr:partnerContribution>Our collaborator will investigate whether conditional animals with targeted alleles in cIAP1 and cIAP2 are resistant to inflammation driven pancreatitis.</gtr:partnerContribution><gtr:piContribution>We have generated double targeted KO (lacking cIAP1 and cIAP2) animals that we are currently characterising for their phenotype with regards to cell death, inflammation and cancer. We have identified that these animals are sensitised to cytokine induced cell death.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Department of Biomedical Molecular Biology</gtr:department><gtr:description>IAP-mediated regulation of SIRS</gtr:description><gtr:id>C990FE31-F896-44D6-9B01-44D0000A100C</gtr:id><gtr:impact>not available yet</gtr:impact><gtr:partnerContribution>Our collaborator will test the in vivo sensitivity of such animals using a model for Systemic Inflammatory Response Syndrome (SIRS).</gtr:partnerContribution><gtr:piContribution>We have generated double targets KO/KI animals of cIAP2/cIAP1 to test the role of the ubiquitin-binding domain of cIAP1. We find that cells from such animals are sensitive cytokine induced cell death.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Francis Crick Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Harnessing cell death mechanisms to improve therapeutic responses in lung cancer</gtr:description><gtr:id>96646413-195C-41B2-A2EB-BDEC20339BB2</gtr:id><gtr:impact>Our experiment resulted in a ms that is currently under review at Cancer Cell</gtr:impact><gtr:partnerContribution>Our collaborators provided an in vivo mouse model for lung cancer in which we could test the therapeutic benefit of a particular drug combination.</gtr:partnerContribution><gtr:piContribution>We conducted several experiments to test what therapeutic combinations would be best suited to kill a particular lung cancer type</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>Immunology Research Centre</gtr:department><gtr:description>MIB-mediated regulation of inflammation</gtr:description><gtr:id>293CD968-C791-45DC-A77D-46BFC4E076CF</gtr:id><gtr:impact>the publication that reports this collaboration is currently under review in Molecular Cell. The work established that Mind Bomb E3 ligases play no role in TNF-mediated activation of cytokines in a panel of cell lines.
The observation contributes to our current understanding of inflammatory signalling and how cross-priming can be achieved, thereby improving anti-cancer strategies.</gtr:impact><gtr:partnerContribution>This collaboration allowed us to investigate the role of Mind bomb E3 ligases in the regulation of TNF-mediated induction of cytokines. Seamus Martin from Trinity College conducted cytokine profiles and TNF dose response curves for us.</gtr:partnerContribution><gtr:piContribution>We provided reagents and cell lines to investigate the role of Mind bomb E3 ligases in cytokine signalling. This provided the Martin lab with important reagents, and will provide them with co-authorship on a publication, which is currently submitted to Molecular Cell</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>UbiCrest analysis of cytokine signalling</gtr:description><gtr:id>7746C9CB-3AAA-43DE-9905-4EDF12C08481</gtr:id><gtr:impact>not available yet</gtr:impact><gtr:partnerContribution>David Komander has provided us with the necessary reagents to conduct the UbiCrest analysis.</gtr:partnerContribution><gtr:piContribution>Using the UbiCrest methodology, we are studying the ubiquitin linkage types that are mediated by IAPs. This provides us with a conceptional framework how inflammatory signalling is achieved and regulated.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>we have generated various cell lines that harbour specific mutations in the cIAP gene</gtr:description><gtr:id>89415936-CB85-44CB-9FE8-66397C5A77C2</gtr:id><gtr:impact>This allows the dissection of inflammation and cell death, and provide important insights for future anti-cancer therapies.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IAP research reagents</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>we developed improved techniques to apply the CRISPR/CAS9 technique to delete specific genes from the genome</gtr:description><gtr:id>8B2D7713-0B35-42D3-A590-4DE3F03E099F</gtr:id><gtr:impact>This will improve the way through which we analyse the function of specific genes.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CRISPR mediated deletion of specific DNA regions</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated various cell lines that lack individual components of the TNF receptor signalling complex</gtr:description><gtr:id>26D0BBE7-A1CD-4B90-8D08-08D112011655</gtr:id><gtr:impact>The generation of specific knockout cell lines will help the dissection of inflammation and cell death in cancer.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CRISPR knockout cells</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We developed a new method that allows the characterisation of specific Ubiquitin linkage types on specific lysine residues. This is important because specific Ubiquitin linkages emanate specific signalling events. However, so far it has been impossible to characterise this. This is the first time that it will be possible to map the linkage types on specific lysine residues.</gtr:description><gtr:id>2B607AE6-9898-4FB7-8D74-A84F8C4626FC</gtr:id><gtr:impact>This represents a paradigm shift in the way Ub signalling will be analysed. This method will help to characterise specific signalling events in vivo.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Prescission mediated characterisation of Ubiquitin linkages on specific lysine residues</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have improve the UbiCrest technique that allows the characterisation of Ubiquitin-dependent signalling events</gtr:description><gtr:id>17EAF89C-90F5-4C27-A109-558B424C1713</gtr:id><gtr:impact>This will allow to dissect the signalling events that control inflammation and cancer development</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ubiquitin restriction analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44C20B6F-D5D7-4E04-A5B5-589052F8D09F"><gtr:id>44C20B6F-D5D7-4E04-A5B5-589052F8D09F</gtr:id><gtr:title>RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7948cf69d3fd9bbc3193aa1a94a63005"><gtr:id>7948cf69d3fd9bbc3193aa1a94a63005</gtr:id><gtr:otherNames>Plaza-Menacho I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FD684B4-38EC-4216-A538-741E6D772BDD"><gtr:id>9FD684B4-38EC-4216-A538-741E6D772BDD</gtr:id><gtr:title>Techniques to Distinguish Apoptosis from Necroptosis.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/949d759f0e46b3cc7052411e2d9bfd02"><gtr:id>949d759f0e46b3cc7052411e2d9bfd02</gtr:id><gtr:otherNames>Feoktistova M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7EDDB6D-873C-4F4D-B3F7-1A6446ED495F"><gtr:id>A7EDDB6D-873C-4F4D-B3F7-1A6446ED495F</gtr:id><gtr:title>An inhibitory mono-ubiquitylation of the Drosophila initiator caspase Dronc functions in both apoptotic and non-apoptotic pathways.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93aeb91dd413b4eab1506212e096e755"><gtr:id>93aeb91dd413b4eab1506212e096e755</gtr:id><gtr:otherNames>Kamber Kaya HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65D66391-C707-436A-A0BF-E6C18B4855B9"><gtr:id>65D66391-C707-436A-A0BF-E6C18B4855B9</gtr:id><gtr:title>Time-Lapse Imaging of Cell Death.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81b3fc19be7b7dee19a86b8010555710"><gtr:id>81b3fc19be7b7dee19a86b8010555710</gtr:id><gtr:otherNames>Wallberg F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B1AB5DB-FA5C-42E1-AE92-98122A8998BC"><gtr:id>3B1AB5DB-FA5C-42E1-AE92-98122A8998BC</gtr:id><gtr:title>The regulatory isoform rPGRP-LC induces immune resolution via endosomal degradation of receptors.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f02324f18f4561f82c79d8b35bdda2ea"><gtr:id>f02324f18f4561f82c79d8b35bdda2ea</gtr:id><gtr:otherNames>Neyen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE56522E-746E-488D-B36C-1E0984FD30BC"><gtr:id>FE56522E-746E-488D-B36C-1E0984FD30BC</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E91E344-AA22-452D-8193-79D4D38F49A0"><gtr:id>0E91E344-AA22-452D-8193-79D4D38F49A0</gtr:id><gtr:title>Analysis of Apoptosis and Necroptosis by Fluorescence-Activated Cell Sorting.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81b3fc19be7b7dee19a86b8010555710"><gtr:id>81b3fc19be7b7dee19a86b8010555710</gtr:id><gtr:otherNames>Wallberg F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3ABFD87-0892-4EED-9B3B-3D7A934E808E"><gtr:id>D3ABFD87-0892-4EED-9B3B-3D7A934E808E</gtr:id><gtr:title>Signal Integration by the I?B Protein Pickle Shapes Drosophila Innate Host Defense.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f71edcfeee53d653c31e6380a6523c25"><gtr:id>f71edcfeee53d653c31e6380a6523c25</gtr:id><gtr:otherNames>Morris O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F4DB222-C251-447A-B218-ABFE3B579BD7"><gtr:id>2F4DB222-C251-447A-B218-ABFE3B579BD7</gtr:id><gtr:title>PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3466d4cb306386a6ec24e3885a13e439"><gtr:id>3466d4cb306386a6ec24e3885a13e439</gtr:id><gtr:otherNames>Bras?-Maristany F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M019217/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>